Serum Interferon-alpha Predicts In-hospital Mortality in Patients Hospitalised with Acute Severe Lupus

Overview

Journal Lupus Sci Med

Specialties Allergy & Immunology
Rheumatology

Date 2023 Sep 4

PMID 37666572

Authors

Keerthi Vardhan Yerram

Ritasman Baisya

Phani Kumar

Rammohan Mylavarapu

Liza Rajasekhar

Affiliations

Soon will be listed here.

Abstract

Objectives: Dysregulation of interferon-alpha (IFN-α) is considered central to the immunological abnormalities observed in SLE. Short-term mortality during high disease activity in lupus is up to 30%. Adenovirus vector-introduced IFN-α into a lupus-prone mouse causes the development of glomerulonephritis and death within weeks. We studied serum IFN-α as a biomarker of in-hospital mortality in patients of SLE with high disease activity.

Methods: Serum IFN-α (ELISA) was measured in patients hospitalised for acute severe lupus in a tertiary care rheumatology unit in India and the levels were compared between survivors and non-survivors. Serum IFN-α was compared with traditional clinical and serological markers associated with disease activity to assess which better prognosticates survival.

Results: In a cohort of 90 patients with a mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) of 19.3 (±5.5), the mean serum IFN-α was 88±144 pg/dL. Levels were undetectable in patients with inactive disease. SLEDAI, anti double stranded DNA (dsDNA) antibody titres and serum IFN-α levels were higher and serum complement (C3) lower in non-survivors (p=0.003, p=0.017, p<0.001, p=0.029, respectively). Serum IFN-α level of 140 pg/mL had a sensitivity of 86.7%, specificity of 94.6%, positive predictive value of 76% and negative predictive value of 83.3% (p<0.001) in predicting mortality. The area under the curve for predicting in-hospital mortality was 0.25 for C3, 0.72 for dsDNA, 0.77 for SLEDAI and 0.92 for serum IFN-α.

Conclusions: Serum IFN-α was better in predicting in-hospital mortality compared with conventional measures of disease activity such as anti-dsDNA, complements and SLEDAI.

Citing Articles

Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.

Sklavenitis-Pistofidis R, Konishi Y, Heilpern-Mallory D, Wu T, Tsakmaklis N, Aranha M Nat Commun. 2025; 16(1):1480.

PMID: 39929803 PMC: 11811135. DOI: 10.1038/s41467-025-56323-w.

References

Dallera M, Cardarelli P, Preston B, Witte A, Davis Jr J . Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005; 64(12):1692-7. PMC: 1755300. DOI: 10.1136/ard.2004.033753. View

Pan L, Lu M, Wang J, Xu M, Yang S . Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2019; 16(1):19-30. PMC: 7040062. DOI: 10.1007/s12519-019-00229-3. View

Zonana-Nacach A, Yanez P, Jimenez-Balderas F, Camargo-Coronel A . Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus. 2007; 16(12):997-1000. DOI: 10.1177/0961203307083175. View

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

Arora S, Isenberg D, Castrejon I . Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res (Hoboken). 2020; 72 Suppl 10:27-46. DOI: 10.1002/acr.24221. View

Suarez-Avellaneda A, Quintana J, Aragon C, Gallego L, Gallego C, Bolanos J . Systemic lupus erythematosus in the intensive care unit: a systematic review. Lupus. 2020; 29(11):1364-1376. DOI: 10.1177/0961203320941941. View

Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S . IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol. 2005; 174(5):2499-506. DOI: 10.4049/jimmunol.174.5.2499. View

Banchereau J, Pascual V . Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25(3):383-92. DOI: 10.1016/j.immuni.2006.08.010. View

Oke V, Gunnarsson I, Dorschner J, Eketjall S, Zickert A, Niewold T . High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019; 21(1):107. PMC: 6489203. DOI: 10.1186/s13075-019-1878-y. View

10.

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

11.

Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K . Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014; 66(6):1583-95. PMC: 4157826. DOI: 10.1002/art.38628. View

12.

Ytterberg S, Schnitzer T . Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982; 25(4):401-6. DOI: 10.1002/art.1780250407. View

13.

Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2001; 9(9):664-71. DOI: 10.1191/096120300674499064. View

14.

Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Barnabei L, Ben Salah E . Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α. Arthritis Rheumatol. 2018; 71(5):756-765. DOI: 10.1002/art.40792. View

15.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

16.

Sharma A, Shamanna S, Kumar S, Wanchu A, Bambery P, Singh S . Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period. Lupus. 2012; 22(2):216-22. DOI: 10.1177/0961203312468626. View

17.

Kavadichanda C, Ganapathy S, Kounassegarane D, Rajasekhar L, Dhundra B, Srivastava A . Clusters based on demography, disease phenotype, and autoantibody status predicts mortality in lupus: data from Indian lupus cohort (INSPIRE). Rheumatology (Oxford). 2023; 62(12):3899-3908. DOI: 10.1093/rheumatology/kead148. View

18.

Guo J, Huang Z, Huang M, He Y, Han B, Ma N . Development of a Novel Simple Model to Predict Mortality in Patients With Systemic Lupus Erythematosus Admitted to the Intensive Care Unit. Front Med (Lausanne). 2021; 8:689871. PMC: 8339434. DOI: 10.3389/fmed.2021.689871. View

19.

Moreno-Torres V, Tarin C, Ruiz-Irastorza G, Castejon R, Gutierrez-Rojas A, Royuela A . Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry. J Clin Med. 2021; 10(24). PMC: 8707218. DOI: 10.3390/jcm10245749. View

20.

Pattanaik S, Muhammed H, Chatterjee R, Naveen R, Lawrence A, Agarwal V . In-hospital mortality and its predictors in a cohort of SLE from Northern India. Lupus. 2020; 29(14):1971-1977. DOI: 10.1177/0961203320961474. View